title: Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study.
abstract: Current use of oral contraceptives (OCs) has been reported to increase breast cancer risk slightly. In 1991/1992, a prospective cohort study specifically designed to examine the role of hormonal contraceptives in relation to breast cancer was conducted in Norway and Sweden. This study was entitled Women's Lifestyle and Health. Of 196,000 invited women aged 30-49 years, 106,844 women answered a 4-page questionnaire. Altogether, 103,027 women providing information on contraceptive use were included in the analysis presented here, and 1,008 primary invasive breast cancers were diagnosed throughout 1999 (end of follow-up). Proportional hazard regression was used to calculate relative risks (RRs) with adjustment for age and other possible confounders. An increased breast cancer risk was observed among women who were current/recent users of OCs of any type at the start of follow-up [RR, 1.6; 96% confidence interval (CI), 1.2-2.1]. Current/recent use (i.e., use in the year preceding cohort enrolment) of combined OCs (RR, 1.5; 95% CI, 1.0-2.0) and progestin-only pills (RR, 1.6; 95% CI, 1.0-2.4) entailed similar levels of increased risk. An increased risk of borderline significance was found among short-term (i.e., less than 13 months) users before age 20 years (RR, 1.3; 95% CI, 1.0-1.7) and before first full-term pregnancy (RR, 1.4; 95% CI, 1.0-1.8). Long-term users of OCs were at a higher risk of breast cancer than never users (test for trend, P = 0.005). Current/recent use of OCs is associated with an increased breast cancer risk. Use of combined OCs and progestin-only pills seem to increase the risk at the same level.
authors.affiliation: Institute of Community Medicine, University of Tromsoe, 9037 Tromsoe, Norway. merethe.kumle@ism.uit.no
authors.forename: Merethe
authors.initials: M
authors.lastname: Kumle
authors.forename: Elisabete
authors.initials: E
authors.lastname: Weiderpass
authors.forename: Tonje
authors.initials: T
authors.lastname: Braaten
authors.forename: Ingemar
authors.initials: I
authors.lastname: Persson
authors.forename: Hans-Olov
authors.initials: HO
authors.lastname: Adami
authors.forename: Eiliv
authors.initials: E
authors.lastname: Lund
mesh_terms: D000328:Adult; D000367:Age Factors; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D015331:Cohort Studies; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008019:Life Style; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D011372:Progestins / Q000009:adverse effects; D011446:Prospective Studies; D012307:Risk Factors; D013548:Sweden / Q000453:epidemiology; D013997:Time Factors; D016387:Women's Health
chemical_list: D003276:Contraceptives, Oral; D011372:Progestins